{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Neoplasms%2C+Castration-resistant", "query": { "condition": "Prostate Neoplasms, Castration-resistant" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 654, "total_pages": 66, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Neoplasms%2C+Castration-resistant&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T22:35:04.508Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04703920", "title": "Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "Metastatic Castration-resistant Prostate Cancer", "Metastatic Ovarian Carcinoma", "Metastic or Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Talazoparib", "type": "DRUG" }, { "name": "Belinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-03-04", "completion_date": "2025-01-02", "has_results": false, "last_update_posted_date": "2025-01-23", "last_synced_at": "2026-07-22T22:35:04.508Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04703920" }, { "nct_id": "NCT06780670", "title": "Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Investigators choice of SoC", "type": "DRUG" }, { "name": "AAA817", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 443, "start_date": "2025-02-27", "completion_date": "2033-07-19", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-07-22T22:35:04.508Z", "location_count": 27, "location_summary": "Los Angeles, California • Palo Alto, California • Santa Barbara, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06780670" }, { "nct_id": "NCT01505868", "title": "Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration Levels of Testosterone", "Castration-Resistant Prostate Carcinoma", "Lymphadenopathy", "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma", "Prostate Carcinoma Metastatic in the Bone", "Prostate Small Cell Carcinoma" ], "interventions": [ { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 170, "start_date": "2012-07-11", "completion_date": "2019-12-09", "has_results": true, "last_update_posted_date": "2021-07-30", "last_synced_at": "2026-07-22T22:35:04.508Z", "location_count": 2, "location_summary": "Detroit, Michigan • Houston, Texas", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01505868" }, { "nct_id": "NCT05551117", "title": "A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostatic Cancer", "Androgen-Independent Prostatic Cancer", "Androgen-Insensitive Prostatic Cancer", "Androgen-Resistant Prostatic Cancer", "Hormone Refractory Prostatic Cancer", "Anal Cancer", "Anal Neoplasm", "Carcinoma, Squamous Cell of Head and Neck", "Head and Neck Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Oral Squamous Cell Carcinoma", "Malignant Melanoma", "Melanoma", "Non-small Cell Lung Cancer", "Non-small Cell Carcinoma", "Small-cell Lung Cancer", "Small Cell Carcinoma" ], "interventions": [ { "name": "vobramitamab duocarmazine 2.0 mg (Arm A)", "type": "BIOLOGICAL" }, { "name": "vobramitamab duocarmazine 2.7 mg (Arm B)", "type": "BIOLOGICAL" }, { "name": "vobramitamab duocarmazine", "type": "BIOLOGICAL" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 192, "start_date": "2023-06-13", "completion_date": "2025-01-23", "has_results": true, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-07-22T22:35:04.508Z", "location_count": 14, "location_summary": "Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Covington", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05551117" }, { "nct_id": "NCT02555189", "title": "Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Prostate Carcinoma Metastatic in the Bone", "Stage IV Prostate Cancer AJCC v7" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 52, "start_date": "2015-12-01", "completion_date": "2023-09-01", "has_results": true, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-07-22T22:35:04.508Z", "location_count": 4, "location_summary": "Ann Arbor, Michigan • Buffalo, New York • New York, New York + 1 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02555189" }, { "nct_id": "NCT07226986", "title": "A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy" ], "interventions": [ { "name": "AMO959", "type": "DRUG" }, { "name": "AAA617", "type": "RADIATION" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 123, "start_date": "2025-12-05", "completion_date": "2029-09-13", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-07-22T22:35:04.508Z", "location_count": 3, "location_summary": "Los Angeles, California • El Paso, Texas • Murray, Utah", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "El Paso", "state": "Texas" }, { "city": "Murray", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226986" }, { "nct_id": "NCT04109729", "title": "Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Radium-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 39, "start_date": "2020-09-16", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-07-22T22:35:04.508Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04109729" }, { "nct_id": "NCT02903160", "title": "Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radium-223 dichloride", "type": "DRUG" }, { "name": "cabazitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2017-01-13", "completion_date": "2021-11-15", "has_results": true, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-07-22T22:35:04.508Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02903160" }, { "nct_id": "NCT04428788", "title": "Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "CC-94676", "type": "DRUG" }, { "name": "CC1083611", "type": "DRUG" }, { "name": "CC1083610", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 131, "start_date": "2020-06-22", "completion_date": "2025-10-28", "has_results": false, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-07-22T22:35:04.508Z", "location_count": 19, "location_summary": "Stanford, California • Washington D.C., District of Columbia • Sarasota, Florida + 14 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Thomasville", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04428788" }, { "nct_id": "NCT01735396", "title": "Abiraterone Acetate Trial in African American Prostate Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 11, "start_date": "2012-12", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2017-05-12", "last_synced_at": "2026-07-22T22:35:04.508Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01735396" } ] }